Form 13-F position report

GINKGO BIOWORKS HOLDINGS INC C

Reported by VANGUARD GROUP INC

DNA CUSIP 37611X100 Manager CIK 0000102909

Reported 132,780,095 shares, up 463,096 (0.3%) from the prior quarter.

Reported value -6.3%; share count 0.3% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q4 2023
Shares 132,780,095 Quarter-end amount reported
Reported value $224,398,360 Fair value at quarter end
Consecutive quarters held 9 Through Q4 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 245528000
2022-03-31 118214000
2022-06-30 206429000
2022-09-30 267930000
2022-12-31 171570964
2023-03-31 147485473
2023-06-30 238639447
2023-09-30 239493769
2023-12-31 224398360
2024-03-31 145993729
2024-06-30 46455679
2024-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

12 quarters
Quarterly reported position history for GINKGO BIOWORKS HOLDINGS INC C held by VANGUARD GROUP INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2024 Reduced 0 -138,964,041 (-100.0%) 0 $0 2024-11-13
Q2 2024 Added 138,964,041 +13,107,377 (10.4%) < 0.01% $46,455,679 2024-08-13
Q1 2024 Reduced 125,856,664 -6,923,431 (-5.2%) < 0.01% $145,993,729 2024-05-10
Q4 2023 Added 132,780,095 +463,096 (0.3%) < 0.01% $224,398,360 2024-02-14
Q3 2023 Added 132,316,999 +4,016,221 (3.1%) < 0.01% $239,493,769 2023-11-14
Q2 2023 Added 128,300,778 +17,409,445 (15.7%) < 0.01% $238,639,447 2023-08-14
Q1 2023 Added 110,891,333 +9,370,053 (9.2%) < 0.01% $147,485,473 2023-05-15
Q4 2022 Added 101,521,280 +15,646,253 (18.2%) < 0.01% $171,570,964 2023-02-10
Q3 2022 Reduced 85,875,027 -860,005 (-1.0%) < 0.01% $267,930,000 2022-11-14
Q2 2022 Added 86,735,032 +57,401,650 (195.7%) < 0.01% $206,429,000 2022-08-12
Q1 2022 Reduced 29,333,382 -212,725 (-0.7%) < 0.01% $118,214,000 2022-05-13
Q4 2021 New 29,546,107 +29,546,107 (0.0%) < 0.01% $245,528,000 2022-02-14

Who else reported the position

388 managers reported GINKGO BIOWORKS HOLDINGS INC C for Q4 2023.

Managers reporting GINKGO BIOWORKS HOLDINGS INC C in Q4 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BAILLIE GIFFORD & CO Reduced 236,292,183 -2,516,640 0.32% $399,333,790 10 qtrs
ARK Investment Management LLC Added 198,606,619 +16,414,434 1.99% $335,645,186 10 qtrs
VIKING GLOBAL INVESTORS LP Unchanged 143,085,126 0 0.89% $241,813,863 10 qtrs
VANGUARD GROUP INC This report Added 132,780,095 +463,096 < 0.01% $224,398,360 9 qtrs
BlackRock Inc Added 72,794,866 +95,599 < 0.01% $123,023,322 9 qtrs
Anchorage Capital Group L L C Unchanged 69,854,593 0 14.05% $118,054,262 10 qtrs
Sumitomo Mitsui Trust Holdings Inc Reduced 58,238,915 -507,245 0.07% $98,423,766 10 qtrs
Nikko Asset Management Americas Inc Reduced 58,238,915 -507,245 0.94% $97,841,377 10 qtrs
MORGAN STANLEY Reduced 48,962,819 -804,601 < 0.01% $82,747,165 10 qtrs
STATE STREET CORPORATION Added 26,053,646 +3,599,910 < 0.01% $44,030,662 9 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2023
Filed
February 14, 2024
Filing type
13F-HR
Position type
CL A SHS

Voting authority reported

Sole
419
Shared
461,957
None
132,317,719

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.